Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial

NCT04355936 is registered in ClinicalTrials.gov with Laboratorio Elea Phoenix S.A. as lead sponsor.

NCT NCT04355936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04355936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial
Lead sponsor
Laboratorio Elea Phoenix S.A.
Phase
Phase 4
Overall status
Completed
Start date
May 19, 2020
Completion date
November 30, 2020
Enrollment
400 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 drug treatment